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Themultiple cell types of brain and blood arise from pluripotent stem cells via progressively more committed
downstream progenitors. In this issue of Cancer Cell, Alcantara Llaguno and colleagues show that identical
genetic drivers give rise to distinct glioma subtypes within differentially committed neural progenitors—a
paradigm well established for leukemias.Glioblastoma multiforme (GBM) is the
most common and most aggressive pri-
mary brain tumor of adults (Louis et al.,
2014; Stupp et al., 2005). Currently,
GBMs are defined and diagnosed by
distinctive histopathological features.
However, genomic profiling has resolved
GBM into multiple subtypes that cannot
be distinguished by histopathological
criteria. Practical overtones for therapy
are embedded within these genetically
defined subtypes. For example, patients
diagnosed with some of the subtypes
will benefit from aggressive therapy,
whereas others will not (Brennan et al.,
2013; Verhaak et al., 2010). Against this
backdrop, an important unresolved ques-
tion is how these subtypes arise. Conceiv-
ably, stochastic accumulation of genetic
changes within a common progenitor
cell could result in histopathologically
similar tumors with different expression
profiles. Alternatively, the different sub-
types of glioma may reflect alternate
cellular origins of the tumor.
A study in this issue of Cancer Cell
(Alcantara Llaguno et al., 2015) addresses
this important question by using a
tamoxifen-activatible Cre system and
cell type-specific promoter/enhancer
elements to ablate a set of tumor suppres-
sors within differentially restricted pro-
genitor cells of the postnatal brain. The
promoter enhancer elements chosen
were Nestin, Ascl1, and NG2 targeting,
respectively: (1) multipotent neural stem
and progenitor cells within the adult
mouse subventricular zone (SVZ) and
subgranular zone (SGZ), (2) partially
committed neural/oligodendrocyte pro-
genitors (NPCs/OPCs) (but not multi-
potent stem cells), and (3) committedOPCs (Figure 1). Crude analogies of
these targets might be found on the
hematopoietic ‘‘wall charts’’ as (1) multi-
potent hematopoietic stem cells, (2)
partially committed myeloid or lymphoid
progenitors, and (3) committed progeni-
tors giving rise to terminally differentiated
myeloid or lymphoid cells.
These workers and others (e.g., Jac-
ques et al., 2010) have shown previously
that ablation of common tumor suppres-
sors within multipotent stem cells in the
adult SVZ gives rise to gliomas in mice.
Building upon prior art, the authors used
their AscL1 driver to show that either
double (Nf1, Trp53) or triple (Nf1, Trp53,
Pten) ablation of the tumor suppressors
generated glioblastomas from partially
committed neural progenitors. Bymultiple
metrics, these gliomas possess stem cell-
like properties equivalent to their counter-
parts derived from multipotent stem and
progenitor cells. Likewise, many of the
Ascl1-targeted glioblastomas grew infil-
tratively in the dorsal mouse brain within
regions marked by gliomas derived
from Nestin-targeted neural stem cells in
earlier studies. Notwithstanding these
similarities, there was a new twist.
A subset of tumors in the Ascl1-tar-
geted mice arose in the ventral brain
(Figure 1). These ventral tumors were
less infiltrative and differentially deco-
rated by the lineagemarkers Gfap, Nestin,
Olig2, and PDGFRa relative to the dorsal
tumors. The authors called the dorsal
(high Gfap/Nestin, low Olig2/PDGFRa)
tumors ‘‘type 1’’ and the ventral (low
Gfap/Nestin, high Olig2/PDGFRa) tumors
‘‘type 2’’. Type 2 tumors appeared
preferentially in double-knockout mice.
Conversely the triple-knockout miceCancer Cell 28were biased to form type 1 tumors. How-
ever, the differential distribution of the
two tumor types was quantitative, rather
than qualitative, in nature. The authors
speculate that the more aggressive
phenotype of the type 1 tumors in the
triple-knockout mice simply masks devel-
opment of the type 2 variants.
How does a common set of genetic
drivers, under control of a common pro-
moter/enhancer element, give rise to two
distinct forms of glioma? Grafting studies
seem to eliminate microenvironment as a
factor. Type 2 tumors retained their orig-
inal phenotype when implanted into the
dorsal striatum—the more typical type 1
tumor site. Expression profiling showed
that the two tumor types clustered sepa-
rately from each other as well as sepa-
rately from normal ventral and dorsal brain
regions. However, when compared to
specific CNS cell populations, the type 2
tumors clustered with OPCs while type 1
gliomas clustered closer to astrocytes.
This cell type-specific segregation led to
the hypothesis that the type 2 tumors
arise from a more restricted progenitor
cell type.
To test this hypothesis, the authors
used their tamoxifen-activated Cre sys-
tem under the control of an NG2-pro-
moter/enhancer to ablate Nf1, Trp53,
and Pten within OPCs. These animals
again developed high-grade gliomas,
but this time, mostly type 2 tumors with
better defined tumor borders, located
preferentially in ventral brain sites.
Expression profiles of NG2-targeted tu-
mors clustered with OPCs and showed
greater alignment with Ascl1-induced
type 2 tumors, suggesting that both
tumors arise from OPCs., October 12, 2015 ª2015 Elsevier Inc. 403
Figure 1. Glioblastoma Diversity Arising from Differentially
Restricted Progenitor Cells
Schematic of sagittal mouse brain slice showing that two different glioblas-
toma subtypes (type 1 gliomas and type 2 gliomas) can be generated by stem
cells or differentially restricted progenitor cells with identical driver mutations.
NSC, neural stem cell; NPC, neural progenitor cell; OPC, oligodendrocyte
progenitor cell; SVZ, subventricular zone; SGZ, subgranular zone.
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restricted to a less restricted
progenitor type, the authors
used their tamoxifen-acti-
vated Cre system under
Nestin control to ablate Nf1,
Trp53, and Pten within multi-
potent neural stem cells in
the SVZ and SGZ. Expression
profiles of the resulting stem
cell-derived tumors clus-
tered closer to Ascl1-induced
type 1 tumors. However, the
authors still noted unique
expression patterns and
lineage-specific signatures
for each GBM subtype de-
pending on their derivation
from multipotent neural stem
cells (Nestin-promoter), bi-
potent neural progenitor cells(Ascl1-promoter), or committed OPCs
(NG2-promoter).
What about human gliomas? Expres-
sion profiles of mouse tumors derived
from all three progenitor cell types
showed the highest enrichment for human
GBM, and not oligodendroglioma or other
CNS or non-CNS tumors. The authors
further compared the murine tumors to
the TCGA humanGBMmolecular subtype
gene sets (Verhaak et al., 2010) and found
that type 1 tumor profiles showed higher
enrichment than type 2 with GBMs of
the mesenchymal subtype.
Other workers have shown that multiple
cell types within the brain, including OPCs
(Galvao et al., 2014; Liu et al., 2011) and
even fully differentiated cells such as neu-
rons (Friedmann-Morvinski et al., 2012),
are capable of giving rise to gliomas, at
least in an experimental setting. What is
new here is the cohesive and self-con-
tained analysis of common genetic
drivers within a set of progressively more
restricted neural progenitors. As the au-
thors point out, mature cell types such as
neurons andastrocytes are unlikely candi-
dates for glioma-cell-of-origin in a physio-
logic setting given their limited self-
renewal potential and the requirement to
accumulate multiple mutations toward404 Cancer Cell 28, October 12, 2015 ª2015the malignant phenotype. The studies of
Alcantara Llaguno et al. (2015) are an
important first step toward putting CNS
cancers on an equal footing with leuke-
mias in terms of mapping tumors to so-
called ‘‘wall charts’’ for organ develop-
ment. In the fullness of time, therapeutic
opportunities may arise from insights into
the requirements and vulnerabilities of
the other progenitor cell types in the
brain that are susceptible to malignant
transformation.
For the road ahead, it will be important
to address the molecular mechanisms
that enable tumor cells to sustain tran-
scriptional similarity to their cell of origin.
Epigenetic analyses of chromatin regula-
tors as well as methylation patterns would
shed light on this question andmight open
a window of opportunity for additional
therapeutic targets. Architectural hetero-
geneity and bidirectional plasticity are
likely to be additional contributing factors
to GBMsubtyping and biology and should
be addressed by future work. Finally, the
notion that subtype differences are cell
autonomous and not impacted by local
environment is difficult to reconcile with
the well documented role of aberrant
vascular niches for glioma stem cells
that mimic the normal neural stem cellElsevier Inc.niche (Gilbertson and Rich,
2007). The role of micro-
environmental cues as a
contributing factor in subtype
identity might merit closer
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